PMID- 22954723
OWN - NLM
STAT- MEDLINE
DCOM- 20130509
LR  - 20131121
IS  - 1531-7048 (Electronic)
IS  - 1065-6251 (Linking)
VI  - 19
IP  - 6
DP  - 2012 Nov
TI  - Human leukocyte antigen-haploidentical stem cell transplantation using 
      T-cell-replete bone marrow grafts.
PG  - 440-7
LID - 10.1097/MOH.0b013e32835822dc [doi]
AB  - PURPOSE OF REVIEW: Once considered too dangerous for all but the sickest of 
      patients, partially human leukocyte antigen (HLA)-mismatched, or 
      HLA-haploidentical, related donor bone marrow transplantation (haploBMT) has seen 
      a revival, thanks to the reduced intensity conditioning (RIC) regimens and 
      graft-versus-host disease (GVHD) prophylaxis with high-dose posttransplantation 
      cyclophosphamide (PT/Cy). RECENT FINDINGS: RIC haploBMT with high-dose PT/Cy is 
      associated with a cumulative incidence of acute grades II-IV GVHD of 
      approximately 30% and incidences of chronic GVHD and nonrelapse mortality (NRM) 
      less than 15%. These results have been confirmed in single and multicenter 
      clinical trials. PT/Cy appears to nullify the detrimental effects of HLA 
      mismatching on the outcome of haploBMT, thereby permitting the selection of haplo 
      donors based upon criteria other than HLA matching. Overall and event-free 
      survivals of RIC haploBMT compare favorably to the outcomes of RIC unrelated 
      adult donor or umbilical cord blood stem cell transplantation. SUMMARY: With its 
      improved toxicity profile, haploBMT is a feasible alternative for patients who 
      lack an HLA-matched donor and can now be applied to treat patients with 
      nonmalignant disorders.
FAU - Fuchs, Ephraim J
AU  - Fuchs EJ
AD  - Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center 
      at Johns Hopkins, Baltimore, Maryland 21287, USA. fuchsep@jhmi.edu
LA  - eng
GR  - P01 CA15396/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - United States
TA  - Curr Opin Hematol
JT  - Current opinion in hematology
JID - 9430802
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Animals
MH  - Bone Marrow Transplantation/immunology/*methods
MH  - Cyclophosphamide/pharmacology
MH  - Graft vs Host Disease/immunology/prevention & control
MH  - HLA Antigens/*immunology
MH  - Haploidy
MH  - Humans
MH  - Immunosuppressive Agents/pharmacology
MH  - Lymphocyte Depletion/methods
MH  - Stem Cell Transplantation/*methods
MH  - T-Lymphocytes/*immunology
EDAT- 2012/09/08 06:00
MHDA- 2013/05/10 06:00
CRDT- 2012/09/08 06:00
PHST- 2012/09/08 06:00 [entrez]
PHST- 2012/09/08 06:00 [pubmed]
PHST- 2013/05/10 06:00 [medline]
AID - 10.1097/MOH.0b013e32835822dc [doi]
PST - ppublish
SO  - Curr Opin Hematol. 2012 Nov;19(6):440-7. doi: 10.1097/MOH.0b013e32835822dc.